Loading...
By Kelly Young
Edited by David G. Fairchild, MD, MPH, and Lorenzo Di Francesco, MD, FACP, FHM
The American Heart Association and the American College of Cardiology have released new guidelines on the appropriate duration of dual antiplatelet therapy (DAPT) in patients with coronary artery disease (CAD).
Overall, DAPT — aspirin plus a P2Y12 receptor inhibitor, such as clopidogrel, prasugrel, or ticagrelor — should be given for a minimal period of time, usually 6 to 12 months.
Longer treatment duration may be considered in patients with higher ischemic risk but lower bleeding risk. For instance, those with acute coronary syndrome and stent implantation should be treated with DAPT for at least 12 months. Shorter treatment duration is reasonable for patients with higher bleeding risk (e.g., those taking oral anticoagulants). Aspirin (81 mg daily) should usually be continued indefinitely in CAD patients.
Separately, in JAMA, researchers report on a clinical prediction tool to help determine which patients undergoing percutaneous coronary intervention would most benefit from prolonged DAPT.
Comment
LINK(S):
DAPT guidelines in Circulation (Free PDF)
JAMA article on DAPT Study clinical prediction tool (Free)
Background: Physician's First Watch coverage of earlier presentation of DAPT Study results (Free)